<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0205245243
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZOLEDRONIC ACID SPC 5MG/100ML SOL. FOR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ZOLEDRONIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1321.8
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gland Pharma Limited " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gland Pharma Limited 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2272]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M05BA08 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zoledronic Acid SPC contains the active substance zoledronic acid.</p><p>Zoledronic acid SPC belongs to a group of medicines called bisphosphonates.</p><p><strong>Osteoporosis</strong></p><p>Osteoporosis is a disease that involves the thinning and weakening of the bones and is common in women after the menopause, but can also occur in men.</p><p>At the menopause, a woman&#39;s ovaries stop producing the female hormone oestrogen, which helps keep bones healthy. Following the menopause bone loss occurs, bones become weaker and break more easily.</p><p>Osteoporosis could also occur in men and women because of the long-term use of steroids, which can affect the strength of bones.</p><p>Many patients with osteoporosis have no symptoms but they are still at risk of breaking bones because osteoporosis has made their bones weaker.</p><p>Decreased circulating levels of sex hormones, mainly oestrogens converted from androgens, also play a role in the more gradual bone loss observed in men.</p><p>In both women and men, Zoledronic Acid strengthens the bone and therefore makes it less likely to break.</p><p>&nbsp;</p><p><strong>Paget&#39;s disease of the bone</strong></p><p><strong>&nbsp;</strong></p><p>It is normal that old bone is removed and is replaced with new bone material. This process is called remodeling.</p><p>Bone remodeling is too rapid and new bone is formed in a disordered fashion, which makes it weaker than normal. If the disease is not treated, bones may become deformed and painful, and may break.</p><p>Zoledronic Acid works by returning the bone remodeling process to normal, securing formation of normal bone, thus restoring strength to the bone.</p><p>You should see your doctor regularly to determine if zoledronic acid SPC is still right for you. Zoledronic acid SPC is not for use in children.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all instructions given to you by your doctor, pharmacist or nurse carefully before you are given zoledronic acid SPC.</p><p>&nbsp;</p><p><strong>You must not be given zoledronic acid SPC:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to zoledronic acid, other bisphosphonates or any of the other ingredients of Zoledronic Acid (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have hypocalcaemia (this means that the levels of calcium in your blood are too low).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are breast-feeding.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before you are given zoledronic acid SPC if you:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are being treated with any other medicine containing zoledronic acid, which is also the active substance of this medicinal product (zoledronic acid SPC is used in adult patients with certain types of cancer to prevent bone complications or to reduce the amount of calcium)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have low blood calcium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; had parathyroid or thyroid surgery (glands in your neck)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have been told you have trouble absorbing minerals in your stomach or intestines (malabsorption syndrome) or have had parts of your intestine removed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have asthma (wheezing) from taking aspirin</p><p>&nbsp;</p><p>A side effect called osteonecrosis of the jaw (ONJ) (bone damage in the jaw) has been reported in the post- marketing setting in patients receiving zoledronic acid SPC for osteoporosis. ONJ can also occur after stopping treatment.</p><p>It is important to try and prevent ONJ developing as it is a painful condition that can be difficult to treat. In order to reduce the risk of developing osteonecrosis of the jaw, there are some precautions you should take.</p><p>&nbsp;</p><p><strong>Before receiving zoledronic acid SPC treatment, tell your doctor, pharmacist or nurse if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have any problems with your mouth or teeth such as poor dental health, gum disease, or a planned tooth extraction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you do not receive routine dental care or have not had a dental check-up for a long time.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are a smoker (as this may increase the risk of dental problems).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have previously been treated with a bisphosphonate (used to treat or prevent bone disorders).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are taking medicines called corticosteroids (such as prednisolone or dexamethasone).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have cancer.</p><p>&nbsp;</p><p>While being treated with zoledronic acid SPC, you should maintain good oral hygiene (including regular teeth brushing) and receive routine dental check-ups.</p><p>If you wear dentures you should make sure these fit properly. If you are under dental treatment or are due to undergo dental surgery (e.g. tooth extractions), inform your doctor about your dental treatment and tell your dentist that you are being treated with zoledronic acid SPC.</p><p>Contact your doctor and dentist immediately if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling, or non-healing of sores or discharge, as these could be signs of osteonecrosis of the jaw.</p><p><strong>Monitoring test</strong></p><p>Your doctor should do a blood test to check your kidney function (levels of creatinine) before each dose of zoledronic acid SPC. It is important for you to drink at least 2 glasses of fluid (such as water), within a few hours before receiving zoledronic acid SPC, as directed by your healthcare provider.</p><p><strong>Children and adolescents</strong></p><p>Zoledronic Acid is not recommended for anyone under 18 years of age. The use of zoledronic acid in children and adolescents has not been studied.</p><p><strong>Other medicines and Zoledronic acid SPC</strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.</p><p>It is important for your doctor to know all the medicines you are taking, especially if you are taking any medicines known to be harmful to your kidneys (e.g. aminoglycosides) or diuretics (&ldquo;waterpills&rdquo;) that may cause dehydration.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Talk to your doctor if you are pregnant, or plan to become pregnant. Zoledronic acid SPC may harm your unborn baby. Zoledronic acid SPC should not be used if you are pregnant.</p><p>Talk to your doctor if you are breastfeeding or plan to breast-feed. It is not known if zoledronic acid SPC passes into your milk and may harm your baby.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p><strong>&nbsp;</strong>If you feel dizzy while taking zoledronic acid, do not drive or use machines until you feel better.</p><p>&nbsp;</p><p><strong>Zoledronic Acid contains sodium</strong></p><p><strong>&nbsp;</strong>This medicinal product contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially &quot;sodium-free&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow carefully all instructions given to you by your doctor or nurse. Check with your doctor or nurse if you are not sure.</p><p>&nbsp;</p><p><strong>Osteoporosis&nbsp;</strong></p><p>The usual dose is 5 mg given as one infusion per year into a vein by your doctor or nurse. The infusion will take at least 15 minutes.</p><p>In case you recently broke your hip, it is recommended that Zoledronic Acid is administered two or more weeks after your hip repair surgery. It is important to take calcium and vitamin D supplements (for example tablets) as directed by your doctor.</p><p>For osteoporosis, Zoledronic Acid works for one year. Your doctor will let you know when to return for your next dose<strong>.</strong></p><p><strong>Paget&#39;s disease</strong></p><p><strong>&nbsp;</strong>For the treatment of Paget&#39;s disease, Zoledronic acid should be prescribed only by physicians with experience.</p><p>&nbsp;</p><p>The usual dose is 5 mg, given to you as one initial infusion into a vein by your doctor or nurse. The infusion will take at least 15 minutes. Zoledronic Acid may work for longer than one year, and your doctor will let you know if you need to be treated again.</p><p>Your doctor may advise you to take calcium and vitamin D supplements (e.g. tablets) for at least the first ten days after being given Zoledronic Acid. It is important that you follow this advice carefully so that the level of calcium in your blood does not become too low in the period after the infusion.</p><p>Your doctor will inform you regarding the symptoms associated with hypocalcaemia.</p><p>&nbsp;</p><p><strong>Zoledronic Acid with food and drink</strong></p><p><strong>&nbsp;</strong></p><p>Make sure you drink enough fluids (at least one or two glasses) before and after the treatment with Zoledronic Acid, as directed by your doctor. It will help to prevent dryness.</p><p>This will help to prevent dehydration. You may eat normally on the day you are treated with Zoledronic Acid. This is especially important in patients who take diuretics (&quot;water pills&quot;) and in elderly patients (age 65 and over).</p><p>&nbsp;</p><p><strong>If you missed a dose of zoledronic acid SPC</strong></p><p><strong>&nbsp;</strong>Call your doctor or healthcare provider to schedule your next dose.</p><p>&nbsp;</p><p><strong>Before stopping zoledronic acid SPC therapy</strong></p><p><strong>&nbsp;</strong></p><p>If you are considering stopping zoledronic acid SPC treatment, please go to your next appointment and discuss this with your doctor.</p><p>Your doctor will advise you and decide how long you should be treated with zoledronic acid SPC. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Side effects related to the first infusion are very common (occurring in more than 30% of patients) but are less common following subsequent infusions.</p><p>The majority of the side effects, such as fever and chills, pain in the muscles or joints, and headache, occur within the first three days following the dose of zoledronic acid. The symptoms are usually mild to moderate and go away within three days.</p><p>Your doctor can recommend a mild pain reliever such as ibuprofen or paracetamol to reduce these side effects. The chance of experiencing these side effects decreases with subsequent doses of zoledronic acid.</p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><p><strong>&nbsp;</strong></p><p>Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving zoledronic acid for the treatment of postmenopausal osteoporosis. It is currently unclear whether zoledronic acid causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received Zoledronic Acid.</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p><strong>&nbsp;</strong></p><p>Swelling, redness, pain and itching to the eyes or eye sensitivity to light.</p><p>&nbsp;</p><p><strong>Very rare:</strong></p><p><strong>&nbsp;</strong></p><p>Talk to your doctor if you have ear pain, discharge from the ear, and/or an ear infection. These could be signs of bone damage in the ear.</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><p><strong>&nbsp;</strong></p><p>Pain in the mouth and/or jaw, swelling or non-healing sores in the mouth or jaw, discharge, numbness or a feeling of heaviness in the jaw, or loosening of a tooth; these could be signs of bone damage in the jaw (osteonecrosis).</p><p>Tell your doctor and dentist immediately if you experience such symptoms while being treated with Zoledronic acid or after stopping treatment.</p><p>Kidney disorders (e.g. decreased urine output) may occur. Your doctor should do a blood test to check your kidney function before each dose of Zoledronic Acid.</p><p>It is important for you to drink at least 2 glasses of fluid (such as water), within a few hours before receiving Zoledronic Acid, as directed by your healthcare provider.</p><p>&nbsp;</p><p>If you experience any of the above side effects, you should contact your doctor immediately. Zoledronic Acid may also cause other side effects</p><p><strong>Very common (may affect more than 1 in 10 people)</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the muscles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the bones and/or joints</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the back, arms or legs, flu-like symptoms (e.g. tiredness, chills, joint and muscle pain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of tiredness and lack of interest</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling unwell</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling and/or pain at the infusion site.</p><p>&nbsp;</p><p>In patients with Paget&#39;s disease, symptoms due to low blood calcium, such as muscle spasms, or numbness, or a tingling sensation especially in the area around the mouth have been reported.</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory tract infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased red cell count</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite, sleeplessness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness which may include reduced alertness and awareness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tingling sensation or numbness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; extreme tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trembling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; temporary loss of consciousness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye infection or irritation or inflammation with pain and redness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spinning sensation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flushing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath, upset stomach</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heartburn</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin reddening</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neck pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiffness in muscles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bones and/or joints</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint swelling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shoulder pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in your chest muscles and rib cage</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint inflammation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscular weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal kidney test results/abnormal frequent urination</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of hands, ankles or feet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thirst</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; toothache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; taste disturbances.</p><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p><strong>&nbsp;</strong></p><p>Unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely. Contact your doctor if you experience pain, weakness or discomfort in your thigh, hip or groin as this may be an early indication of a possible fracture of the thigh bone Low levels of phosphate in the blood.</p><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><p><strong>&nbsp;</strong></p><p>Severe allergic reactions including dizziness and difficulty breathing, swelling mainly of the face and throat, decreased blood pressure, dehydration secondary to post-dose symptoms such as fever, vomiting and diarrhea.</p><p><strong>Reporting of side effects</strong></p><p><strong>&nbsp;</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor, pharmacist or nurse knows how to store Zoledronic Acid properly.</p><p>Store below 30˚C</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>After opening the bag, the product should be used immediately in order to avoid microbial contamination. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and</p><p>&nbsp;</p><p>would normally not be longer than 24 hours at 2&deg;C - 8&deg;C. Allow the refrigerated solution to reach room temperature before administration.</p><p>Do not use this medicine after the expiry date which is stated on the carton after EXP.</p><p>&nbsp;</p><p>The unopened bag does not require any special temperature storage conditions. Store in the original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zoledronic acid SPC infusion is a clear colorless solution free from visible extraneous matter, filled in USP Type-I Tubular Glass Vial.</p><p>Pack of 1 vial.</p><p>&nbsp;</p><p><strong>Other Ingredient</strong>: Mannitol, Sodium Citrate Dihydrate &amp; Water for Injection</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                NA
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>MARKETING AUTHORIZATION HOLDER:</strong></p><p><em>Sudair Pharma Company (SPC)</em></p><p><em>&nbsp;King Fahad road, Building 911- The First Round Riyadh, Saudi Arabia</em></p><p><em>Tel: +966-11-4668193</em></p><p><em>&nbsp;Fax: +966-11-4668195</em></p><p><em>&nbsp;Email: </em><em>info@sudairpharma.com</em></p><p><em>&nbsp;Mailing: P.O. Box 19047 Riyadh, Saudi Arabia</em></p><p><em>&nbsp;</em></p><p><strong>Manufacturer:</strong></p><p><em>Gland Pharma Limited,</em></p><p><em>Survey No.: 143 &ndash; 148, 150 &amp; 151,</em></p><p><em>Near Gandimaisamma Cross Roads,</em></p><p><em>D.P. Pally, Quthubullapur Mandal, Ranga Reddy District</em></p><p><em>Hyderabad, Telangana &ndash; 500043</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي زوليدرونيك اس بي سي على مادة حمض الزوليدرونيك.</p><p>ينتمي حمض زوليدرونيك اس بي سي إلى مجموعة من الأدوية تسمى أدوية البيسفوسفونيتات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هشاشة العظام:</strong></p><p dir="RTL">هو مرض عبارة عن ترقق العظام وضعفها، وهو شائع في النساء بعد انقطاع الطمث ، ولكن يمكن أن يحدث أيضاً عند الرجال.</p><p>في مرحلة انقطاع الطمث ، وتوقف المبيض للمرأة عن إنتاج هرمون الأستروجين الأنثوي ، مما يساعد على الحفاظ على صحة العظام. بعد حدوث انقطاع الطمث في العظام، تصبح العظام أضعف وتكسر بسهولة أكبر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ممكن أن يحدث هشاشة العظام أيضًا لدى الرجال والنساء بسبب الاستخدام طويل الأمد للستيرويدات ، والتي يمكن أن تؤثر على قوة العظام.</p><p dir="RTL">العديد من المرضى الذين يعانون من مرض هشاشة العظام ليس لديهم أي أعراض، ولكنهم عرضة لكسر العظام لأن هشاشة العظام جعل عظامهم أضعف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كما أن انخفاض مستويات الدوران للهرمونات الجنسية ، وخاصةً الإستروجين المحول من الأندروجينات ، يلعب أيضًا دورًا في فقدان العظام التدريجي الذي لوحظ لدى الرجال.</p><p dir="RTL">في كل من النساء والرجال ، يقوي حامض الزوليدرونيك العظام وبالتالي يجعله أقل عرضة للكسر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مرض باجيت للعظم:</strong></p><p>من الطبيعي إزالة العظم القديم واستبداله بمواد عظمية جديدة. هذه العملية تسمى إعادة التصميم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعادة تشكيل العظام بشكل سريع للغاية ويتشكل العظم الجديد بطريقة غير مرتبة ، مما يجعله أضعف من المعتاد، وإذا لم يتم علاج المرض ، فقد تصبح العظام مشوهة ومؤلمة وقد تنكسر.</p><p dir="RTL">يعمل زوليدرونيك اس بي سي عن طريق عملية إعادة تشكيل العظم إلى الوضع الطبيعي ، مما يضمن تكوين العظام الطبيعية ، وبالتالي استعادة القوة للعظام.</p><p dir="RTL">يجب زيارة الطبيب المعالج لك بشكل دوري، لتحديد ما إذا كان استعمال زوليدرونيك اس بي سي لا يزال ملائمًا لك أم لا. ولا يُوصى باستخدام زوليدرونيك اس بي سي للأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتبع كافة تعليمات الطبيب المعالج لك أو الصيدلي الخاص بك أو الممرض(ة) المتابع(ة) لك، قبل استعمال زوليدرونيك اس بي سي.</p><p dir="RTL"><strong>يجب عدم استعمال زوليدرونيك اس بي سي في الحالات التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية من حامض الزوليدرونيك ، أو البايفوسفونيت أو أي من المكونات الأخرى للزولدرونيك اس بي سي (المدرجة في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من نقص كلس الدم (وهذا يعني أن مستويات الكالسيوم في الدم منخفضة للغاية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كان لديك مشاكل في الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنتي حامل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنتي تقومي بالرضاعة</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث مع الطبيب المعالج لك قبل استعمال زوليدرونيك اس بي سي إذا كنت تعاني من أي من الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعالج بأي دواء آخر يحتوي على حمض زوليدرونيك، الذي يُعتبر أيضًا المادة الفعالة لهذا المنتج الدوائي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدم زوليدرونيك اس بي سي للبالغين المصابين بأنواع معينة من مرض السرطان، وللوقاية من المضاعفات التي تُصَيب العظام أو لتقليل كمية الكالسيوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من انخفاض نسبة الكالسيوم في الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات في الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد خضعت لجراحة في الغدة الجار درقية أو الغدة الدرقية (غدد في العنق).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان قد أخبرك الطبيب المعالج أنك تعاني من مشكلة في امتصاص المعادن في المعدة أو الأمعاء (متلازمة سوء الامتصاص) أو قد خضعت لإزالة أجزاء من الأمعاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الربو بعد تناول الأسبرين.</p><p dir="RTL">قد تم الإبلاغ عن أثر جانبي يسمى نخر في عظام الفك (ONJ) وهو عبارة عن تلف بعظام الفك (في مرحلة ما بعد طرح الدواء في الأسواق)، وأصاب ذلك المرضى الذين يستعملون حمض زوليدرونيك لعلاج هشاشة العظام. قد يحدث نخر عظام الفك أيضًا بعد التوقف عن العلاج.</p><p dir="RTL">من المهم محاولة الوقاية من الإصابة بنخر عظام الفك، لأنها حالة مؤلمة يمكن أن يكون من الصعب علاجها. وهناك بعض الاحتياطات التي يجب اتخاذها للحد من خطورة الإصابة بنخر عظام الفك.</p><p dir="RTL"><strong>أخبر الطبيب المعالج لك أو الصيدلي الخاص بك أو الممرض(ة) المتابع(ة) لك، قبل استعمال زوليدرونيك اس بي سي في الحالات التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من مشكلات بالفم أو الأسنان مثل سوء حالة الأسنان أو أمراض اللثة أو إذا كان من المقرر أن تخضع لعملية خلع أسنان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت لا تتلقى رعاية روتينية للأسنان أو لم تخضع لفحص الأسنان منذ فترة طويلة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُدخنًا (لأن ذلك قد يزيد من مخاطر التعرض لمشكلات الأسنان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عُوَلجت في السابق بأدوية الباسيفوسفونينات (لعلاج اضطرابات العظام أو الوقاية منها).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية تسمي الكورتيكوستيرويد (مثل بريدنيزولون أو ديكساميثازون).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالسرطان.</p><p dir="RTL">يجب عليك الحفاظ على نظافة فمك جيدًا خلال فترة العلاج بزوليدرونيك اس بي سي (بما في ذلك تنظيف الأسنان بالفرشاة بشكل دوري) والخضوع لفحوصات الأسنان الروتينية.</p><p dir="RTL">إذا كنت ترتدي أطقم أسنان، فيجب التأكد من أن هذه الأطقم تناسبك بشكل ملائم. أخبر الطبيب المعالج لك عن علاج الأسنان الخاص بك وأخبر طبيب الأسنان المتابع لك أنك تُعالج بزوليدرونيك اس بي سي، إذا كنت تخضع لعلاج الأسنان أو ستخضع لجراحة الأسنان (مثل خلع الأسنان).</p><p dir="RTL">اتصل بالطبيب المعالج لك وطبيب الأسنان المتابع لك على الفور إذا كنت تعاني من مشكلات في الفم أو اللثة مثل تخلخل الأسنان أو ألم بالأسنان أو تورم اللثة أو عدم التئام التقرحات أو عدم التئام مواضع خلع الأسنان، فقد تكون هذه علامات تدل على الإصابة بنخر عظام الفك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اختبار المتابعة:</strong></p><p dir="RTL">يجب على الطبيب المعالج لك إجراء فحص دم للتحقق من وظائف الكلى (مستويات الكرياتينين) قبل استعمال كل جرعة من &nbsp;زوليدرونيك اس بي سي. ومن المهم بالنسبة لك أن تشرب ما لا يقل عن كوبين من السوائل (على سبيل المثل الماء)، في غضون بضعة ساعات قبل استعمال زوليدرونيك اس بي سي وفقًا لتوجيهات مقدم الرعاية الصحية الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون:</strong></p><p dir="RTL">لا ينصح باستخدام زوليدرونيك اس بي سي لأي شخص يقل عمره عن 18 عامًا. حيث لم يتم دراسة استخدام حمض الزوليدرونيك في الأطفال والمراهقين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام ادوية اخرى مع زوليدرونيك اس بي سي</strong></p><p dir="RTL">أخبر الطبيب المعالج لك أو الصيدلي الخاص بك أو الممرض(ة) المتابع(ة) لك إذا كنت تتناول أو قد تناولت مؤخرًا أو قد تتناول أية أدوية أخرى.</p><p dir="RTL">من المهم أن يعرف الطبيب المعالج لك كافة الأدوية التي تتناولها، خاصة إذا كنت تتناول أي أدوية معروفة بأنها تضر الكليتين (مثل أدوية الأمينُوجْليكُوزيد) أو مُدِرُّات البَول (حبوب المدرة للبول) التي قد تسبب الجفاف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية:</strong></p><p dir="RTL">استشيري الطبيب المعالج لكِ، إذا كنتِ حاملًا أو تخططين للحمل. قد يضر زوليدرونيك اس بي سي بالجنين. يجب عدم استخدام زوليدرونيك اس بي سي ، إذا كنتِ حاملًا.</p><p dir="RTL">استشيري الطبيب المعالج لكِ، إذا كنتِ مرضعة أو تخططين للرضاعة الطبيعية. &nbsp;لانه من غير المعروف ما إذا كان زوليدرونيك اس بي سي يفرز في حليب الأم وقد يضر طفلك.</p><p><strong>القيادة واستخدام الآلات:</strong></p><p>إذا كنت تشعر بدوخة خلال فترة تناوُل زوليدرونيك اس بي سي فلا تقود السيارة أو تستخدم أي أدوات أو آلات حتى تشعر بتحسن.</p><p dir="RTL"><strong>زوليدرونيك يحتوي على الصوديوم:</strong></p><p dir="RTL">يحتوي هذا المنتج الطبي على أقل من 1 مل مول صوديوم (23 ملغ) لكل قنينة ، بمعنى &quot;خالٍ من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتبع تعليمات الطبيب المعالج لك أو الممرض(ة) المتابع(ة) لك بحرص. وتحقق من الطبيب المعالج لك أو الممرض(ة) المتابع(ة) لك إذا لم تكن متأكدًا من كيفية الاستعمال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هشاشة العظام:</strong></p><p dir="RTL">الجرعة المعتادة هي 5 ملجم تعطى عن طريف الحقن الوريدي مرة واحدة كل سنة من قبل الطبيب أو الممرضة. حيث يستغرق 15 دقيقة على الأقل.</p><p dir="RTL">وفي حال كسر الورك في الآونة الاخيرة فمن المستحسن ان يعطى زوليدرونيك اس بي سي كل اسبوعين او اكثر بعد جراحة اصلاح الورك. من المهم تناول مكملات الكالسيوم وفيتامين د (أقراص على سبيل المثال) حسب توجيهات الطبيب.</p><p dir="RTL">يستخدم زوليدرونيك اس بي سي لمرة واحدة خلال العام لمرضى هشاشة العظام. سوف يخبرك طبيبك بموعد العودة للجرعة التالية.</p><p dir="RTL"><strong>مرض باجيت:</strong></p><p dir="RTL">لعلاج مرض باجيت ، يجب وصف الزولدرونيك اس بي سي فقط من قبل الأطباء ذوي الخبرة.</p><p dir="RTL">الجرعة المعتادة هي 5 ملجم ، تعطى لك كبداية أولية في الوريد من قبل الطبيب أو الممرضة. تستغرق مدة الحق 15 دقيقة على الأقل. حيث قد يعمل زوليدرونيك اس بي سي لمدة تزيد عن عام واحد ، وسوف يخبرك طبيبك إذا كنت بحاجة إلى العلاج مرة أخرى.</p><p dir="RTL">قد ينصحك طبيبك بتناول مكملات الكالسيوم وفيتامين د (على سبيل المثال ، أقراص) لمدة عشرة أيام على الأقل بعد إعطاؤك زوليدرونيك اس بي سي. حيث من المهم أن تتبع هذه النصيحة بعناية حتى لا يصبح مستوى الكالسيوم في الدم منخفضًا للغاية في الفترة التالية للجرعة.</p><p dir="RTL">سيعلمك الطبيب عن الأعراض المرتبطة بنقص كلس الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>زوليدرونيك اس بي سي مع الطعام والشراب:</strong></p><p dir="RTL">تأكد من شرب كمية كافية من السوائل (على الأقل كأس أو كأسين) قبل وبعد العلاج باستخدام زوليدرونيك اس بي سي، وفقًا لتوجيهات الطبيب. حيث انه سوف يساعد على منع الجفاف.</p><p dir="RTL">ويمكنك تناول الطعام بشكل طبيعي في اليوم الذي يتم فيه علاجك باستخدام زوليدرونيك اس بي سي. هذا مهم بشكل خاص في المرضى الذين يتناولون مدرات البول (&quot;حبوب الماء&quot;) والمرضى المسنين (سن 65 وما فوق).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت جرعة من حمض زوليدرونيك اس بي سي:</strong></p><p dir="RTL">إذا نسيت جرعة من حمض زوليدرونيك اس بي سي ، فاتصل بالطبيب المعالج لك أو مقدم الرعاية الصحية الخاص بك لتحدد موعد الجرعة التالية.</p><p>&nbsp;</p><p><strong>قبل التوقف عن العلاج بحمض زوليدرونيك اس بي سي:</strong></p><p>إذا كنت تفكر في التوقف عن العلاج بحمض زوليدرونيك اس بي سي ، يُرجى الذهاب إلى موعدك التالي ومناقشة ذلك مع الطبيب المعالج لك.</p><p>سيقدم الطبيب المعالج لك النصيحة، وسيقرر المدة التي يجب فيها الاستمرار في استخدام زوليدرونيك اس بي سي او لا.</p><p>إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر الطبيب المعالج لك أو الصيدلي الخاص بك أو الممرض(ة) المتابعة(ة) لك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد يُسبب هذا الدواء آثارًا جانبية مثله مثل كافة الأدوية، على الرغم من عدم حدوثها لكافة المرضى. الآثار الجانبية المتعلقة بالحقن الأول شائعة جدا (تحدث في أكثر من 30 ٪ من المرضى) ولكنها أقل شيوعا بعد الحقن اللاحقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">غالبية الآثار الجانبية ، مثل الحمى والقشعريرة ، الألم في العضلات أو المفاصل ، والصداع ، تحدث خلال الأيام الثلاثة الأولى بعد جرعة الزوليدرونيك اس بي سي. وعادة ما تكون الأعراض خفيفة إلى معتدلة وتختفي في غضون ثلاثة أيام.</p><p dir="RTL">يمكن أن يوصي طبيبك بمسكنات الألم الخفيفة مثل الأيبوبروفين أو الباراسيتامول للحد من هذه الآثار الجانبية. وتقل فرصة مواجهة هذه الآثار الجانبية مع الجرعات التالية من الزوليدرونيك اس بي سي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>عام (قد يؤثر على شخص واحد من كل 10 أشخاص)</strong></p><p dir="RTL">وقد لوحظ عدم انتظام ضربات القلب (الرجفان الأذيني) في المرضى الذين يتلقون زوليدرونيك اس بي سي لعلاج هشاشة العظام بعد سن اليأس. ومن غير الواضح حاليًا ما إذا كان الزوليدرونيك اس بي سي يسبب هذا الإيقاع غير المنتظم للقلب ، لكن يجب عليك إبلاغ طبيبك إذا كنت تعاني من هذه الأعراض بعد تلقي زوليدرونيك اس بي سي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائع (قد يؤثر على شخص واحد من بين كل 100 شخص)</strong></p><p dir="RTL">تورم واحمرار وألم وحكة في العين أو حساسية العين للضوء</p><p dir="RTL"><strong>نادر جدا:</strong></p><p dir="RTL">تحدث إلى طبيبك إذا كنت تعاني من ألم في الأذن ، أو إفرازات من الأذن ، و / أو عدوى الأذن. قد تكون هذه علامات على تلف العظام في الأذن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروف (لا يمكن تقدير التردد من البيانات المتاحة)</strong></p><p dir="RTL">ألم في الفم و/أو الفك ، تورم أو قرح غير شافية في الفم أو الفك ، إفرازات ، خدر أو شعور بثقل في الفك ، أو تخفيف الأسنان. هذه يمكن أن تكون علامات تلف العظام في الفك (تنخر العظم).</p><p dir="RTL">أخبر طبيبك وطبيب الأسنان فوراً إذا واجهت هذه الأعراض أثناء علاجك بزولدرونيك اس بي سي أو بعد التوقف عن العلاج.</p><p dir="RTL">قد تحدث اضطرابات في الكلى (على سبيل المثال ، انخفاض في إنتاج البول). يجب أن يقوم الطبيب بإجراء فحص دم للتحقق من وظائف الكلى قبل كل جرعة من زوليدرونيك اس بي سي.</p><p dir="RTL">من المهم شرب كوبين على الأقل من السوائل (مثل الماء) ، في غضون ساعات قليلة قبل استخدام زوليدرونيك اس بي سي ، وفقًا لتوجيهات من مقدم الرعاية الصحية الخاص بك.</p><p dir="RTL">إذا كنت تواجه أيًا من الأعراض الجانبية المذكورة أعلاه ، فيجب عليك الاتصال بالطبيب على الفور. قد يسبب حمض زوليدرونيك أيضًا آثارًا جانبية أخرى</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائع جدا (قد يؤثر على أكثر من 1 من كل 10 أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>عام (قد يؤثر على شخص واحد من كل 10 أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الراس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيؤ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العظام و / أو المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الظهر أو الذراعين أو الساقين ، أعراض تشبه أعراض الأنفلونزا (مثل التعب والقشعريرة وآلام المفاصل والعضلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب وعدم الاهتمام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بعدم الراحة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم و / أو ألم في موقع التسريب.</p><p dir="RTL">في المرضى الذين يعانون من مرض باجيت ، يتم الإبلاغ عن الأعراض الناجمة عن انخفاض الكالسيوم في الدم ، مثل تشنجات العضلات، أو خدر، أو الإحساس بالوخز خاصة في المنطقة المحيطة بالفم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائع (قد يؤثر على شخص واحد من بين كل 100 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أنفلونزا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات الجهاز التنفسي العلوي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الخلايا الحمراء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس الذي قد يشمل تقليل اليقظة والوعي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالوخز أو التنميل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب الشديد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرتجف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان مؤقت للوعي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى العين أو تهيج أو التهاب مع ألم واحمرار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بالدوران.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدفق مائى &ndash; صرف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس ، واضطراب في المعدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجع بطن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فم جاف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرق الزائد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الم الرقبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب في العضلات و/او العظام و/او المفاصل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم المفاصل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنجات العضلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الم الكتف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في عضلات الصدر والقفص الصدري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج اختبار الكلى غير طبيعية \ كثرة التبول غير طبيعية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اليدين اوالكاحلين او القدمين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العطش.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجع أسنان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الذوق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادر (قد يؤثر على 1 من كل 1000 شخص)</strong></p><p dir="RTL">قد يحدث كسر غير عادي في عظم الفخذ خاصة عند المرضى الذين يعانون من علاج هشاشة العظام على المدى الطويل. اتصل بطبيبك إذا كنت تعاني من الألم أو الضعف أو عدم الراحة في الفخذ أو الورك أو الفخذ حيث أن هذا قد يكون مؤشرا مبكرا لكسور في عظمة الفخذ.<br />نقص فى مستويات الفوسفات بالدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروف (لا يمكن تقدير التردد من البيانات المتاحة)</strong></p><p dir="RTL">تفاعلات الحساسية الشديدة بما في ذلك الدوخة وصعوبة في التنفس ، وتورم أساسا من الوجه والحلق ، وانخفاض ضغط الدم والجفاف الثانوي لأعراض ما بعد الجرعة مثل الحمى والقيء والإسهال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا حصلت على أي آثار جانبية ، تحدث مع طبيبك أو الصيدلي أو الممرضة. يتضمن ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يعرف طبيبك أو الصيدلي أو الممرضة كيفية تخزين زوليدرونيك اس بي سي بشكل صحيح.</p><p dir="RTL">يحفظ في درجة حرارة اقل من 30 درجة مئوية. ابق هذا الدواء بعيدا عن متناول الأطفال.</p><p dir="RTL">بعد فتح العبوة ، يجب استخدام المنتج على الفور لتجنب التلوث الجرثومي. إذا لم يتم استخدامها على الفور، فإن أوقات وظروف التخزين أثناء الاستخدام هي مسئولية المستخدم، ولا تزيد عادةً عن 24 ساعة عند 2 درجة مئوية إلى 8 درجات مئوية. اترك المحلول المبرد للوصول إلى درجة حرارة الغرفة قبل الاستخدام.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الذي ينص على الكرتون.</p><p dir="RTL">لا تتطلب العبوة المفتوحة أي ظروف خاصة لتخزين الحرارة. تخزن في مغلفها الأصلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">زوليدرونيك اس بي سي عبارة عن محلول للحقن الوريدي وهو محلول عديم اللون نقي خالي من الأجسام الدقيقة الظاهرة، مُعبأ في عبوة زجاجية أنبوبية من النوع الأول وفقًا لمواصفات دستور الدواء الأمريكي.</p><p>يتوفر في عبوة تحتوي على زجاجة واحدة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>مكونات اخرى: مانيتول وصوديوم ثنائي الهيدروجين وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسويِق:</strong></p><p dir="RTL">شركة سدير فارما (SPC)</p><p dir="RTL">طريق الملك فهد، مبنى 911-الدوار الارضي</p><p dir="RTL">الرياض -المملكة العربية السعودية</p><p dir="RTL">هاتف: 4668193-11-966+</p><p dir="RTL">فاكس: 4668195-11-966+</p><p dir="RTL">البريد الإلكتروني: info@sudairpharma.com</p><p dir="RTL">عنوان المراسلة: صندوق بريد رقم: 19047</p><p dir="RTL">الرياض -المملكة العربية السعودية</p><p dir="RTL"><strong>جهة التَّصنيع:</strong></p><p dir="RTL">شركة مختبرات دكتور ريدي، ليمتد - الوحدة السابعة الخاصة بالتصنيع</p><p dir="RTL">قطع أرض من رقم P1 إلى P9، المرحلة الثالثة</p><p dir="RTL">دوفادا، فزيز، فيساخاباثنام</p><p dir="RTL">ولاية اندرا براديش، الهند - 046 530</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zoledronic Acid 5 mg/ 100 ml solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each bag of solution contains zoledronic acid monohydrate corresponding to 5 mg zoledronic acid This medicinal product contains 2.2 – 3.1 mg of sodium.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion
Clear and colorless solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of osteoporosis in post-menopausal women in adult men</p><p>at increased risk of fracture, including those with a recent low-trauma hip fracture. Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women</p><p>in adult men</p><p>at increased risk of fracture.</p><p>Treatment of Paget&#39;s disease of the bone in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Posology</u></em></p><p>Patients must be appropriately hydrated prior to administration of Zoledronic Acid. This is especially important</p><p>for the elderly (&ge; 65 years) and for patients receiving diuretic therapy.</p><p>Adequate calcium and vitamin D intake are recommended in association with Zoledronic Acid administration.</p><p><em><u>Osteoporosis</u></em></p><p>For the treatment of post-menopausal osteoporosis, osteoporosis in men and the treatment of osteoporosis associated with long-term systemic glucocorticoid therapy, the recommended dose is a single intravenous infusion of 5 mg Zoledronic Acid administered once a year.</p><p>The optimal duration of bisphosphonate treatment for osteoporosis has not been established. The need for continued treatment should be re-evaluated periodically based on the benefits and potential risks of Zoledronic Acid on an individual patient basis, particularly after 5 or more years of use.</p><p>In patients with a recent low-trauma hip fracture, it is recommended to give the Zoledronic Acid infusion two or more weeks after hip fracture repair (see section 5.1). In patients with a recent low-trauma hip fracture, a loading dose of 50,000 to 125,000 IU of vitamin D given orally or via the intramuscular route is recommended prior to the first Zoledronic Acid infusion.</p><p>&nbsp;</p><p><em><u>Paget&#39;s disease</u></em></p><p>For the treatment of Paget&#39;s disease, Zoledronic Acid should be prescribed only by physicians with experience in the treatment of Paget&#39;s disease of the bone. The recommended dose is a single intravenous infusion of 5 mg Zoledronic Acid.</p><p>In patients with Paget&#39;s disease, it is strongly advised that adequate supplemental calcium corresponding to at least 500 mg elemental calcium twice daily is ensured for at least 10 days following Zoledronic Acid administration (see section 4.4).</p><p>Re-treatment of Paget&#39;s disease: After initial treatment with Zoledronic Acid in Paget&#39;s disease, an extended remission period is observed in responding patients. Re- treatment consists of an additional intravenous infusion of 5 mg Zoledronic Acid after an interval of one year or longer from initial treatment in patients who have relapsed. Limited data on re-treatment of Paget&#39;s disease are available (see section 5.1).</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>Patients with renal impairment</em></p><p>Zoledronic Acid is contraindicated in patients with creatinine clearance &lt; 35 ml/min (see sections 4.3 and 4.4). No</p><p>dose adjustment is necessary in patients with creatinine clearance &ge; 35 ml/min.</p><p><em>Patients with hepatic impairment</em></p><p>No dose adjustment is required (see section 5.2).</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Older people (&ge; 65 years)</u></em></p><p>No dose adjustment is necessary since bioavailability, distribution and elimination were similar in elderly patients and younger subjects.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Pediatric population</u></em></p><p>The safety and efficacy of Zoledronic Acid in children and adolescents below 18 years of age have not been established. No data are available.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Method of administration</u></em></p><p>Intravenous use.</p><p>Zoledronic Acid (5 mg in 100 ml ready-to-infuse solution) is administered via a vented infusion line and given at a constant infusion rate. The infusion time must not be less than 15 minutes. For information on the infusion of Zoledronic Acid, see section 6.6.</p><p>&#39;Patients treated with zolendronic acid should be given the package leaflet and the patient reminder card.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance, to any bisphosphonates or to any of the excipients listed insection 6.1.
-	Patients with hypocalcaemia (see section 4.4).
-	Severe renal impairment with creatinine clearance < 35 ml/min (see section 4.4).
-	Pregnancy and breast-feeding (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Renal function</u></em></p><p>The use of Zoledronic Acid in patients with severe renal impairment (creatinine clearance &lt; 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.</p><p>Renal impairment has been observed following the administration of zoledronic acid (see section 4.8), especially in patients with pre-existing renal dysfunction or other risks including advanced age, concomitant nephrotoxic medicinal products, concomitant diuretic therapy (see section 4.5), or dehydration occurring after zoledronic acid administration. Renal impairment has been observed in patients after a single administration. Renal failure requiring dialysis or with a fatal outcome has rarely occurred in patients with underlying renal impairment or with any of the risk factors described above.</p><p>The following precautions should be taken into account to minimise the risk of renal adverse reactions:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Creatinine clearance should be calculated based on actual body weight using the Cockcroft-Gault formula before each Zoledronic Acid dose.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Transient increase in serum creatinine may be greater in patients with underlying impaired renalfunction.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Monitoring of serum creatinine should be considered in at-risk patients.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Zoledronic Acid should be used with caution when concomitantly used with other medicinal productsthat could impact renal function (see section 4.5).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Patients, especially elderly patients and those receiving diuretic therapy, should be appropriatelyhydrated prior to administration of Zoledronic Acid.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; A single dose of Zoledronic Acid should not exceed 5 mg and the duration of infusion should be at least 15 minutes (see section 4.2).</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Hypocalcaemia</u></em></p><p>Pre-existing hypocalcaemia must be treated by adequate intake of calcium and vitamin D before initiating therapy with Zoledronic Acid (see section 4.3). Other disturbances of mineral metabolism must also be effectively treated (e.g. diminished parathyroid reserve, intestinal calcium malabsorption). Physicians should consider clinical monitoring for these patients.</p><p>Elevated bone turnover is a characteristic of Paget&#39;s disease of the bone. Due to the rapid onset of effect of zoledronic acid on bone turnover, transient hypocalcaemia, sometimes symptomatic, may develop and is usually maximal within the first 10 days after infusion of Zoledronic Acid (see section 4.8).</p><p>Adequate calcium and vitamin D intake are recommended in association with Zoledronic Acid administration. In addition, in patients with Paget&#39;s disease, it is strongly advised that adequate supplemental calcium corresponding to at least 500 mg elemental calcium twice daily is ensured for at least 10 days following Zoledronic Acid administration (see section 4.2).</p><p>Patients should be informed about symptoms of hypocalcaemia and receive adequate clinical monitoring during the period of risk. Measurement of serum calcium before infusion of Zoledronic Acid is recommended for patients with Paget&acute;s disease.</p><p>Severe and occasionally incapacitating bone, joint and/or muscle pain have been infrequently reported in patients taking bisphosphonates, including Zoledronic Acid (see section 4.8).</p><p><em><u>Osteonecrosis of the jaw (ONJ)</u></em></p><p>ONJ has been reported in the post-marketing setting in patients receiving Zoledronic Acid for osteoporosis (see section 4.8).</p><p>The start of treatment or of a new course of treatment should be delayed in patients with unhealed open soft tissue lesions in the mouth. A dental examination with preventive dentistry and an individual benefit-risk assessment is recommended prior to treatment with Zoledronic Acid in patients with concomitant risk factors.</p><p>&nbsp;</p><p>The following should be considered when evaluating a patient&#39;s risk of developing ONJ:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Potency of the medicinal product that inhibits bone resorption (higher risk for highly potent compounds), route of administration (higher risk for parenteral administration) and cumulative dose of bone resorption therapy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Concomitant therapies: corticosteroids, chemotherapy, angiogenesis inhibitors, radiotherapy to head and neck.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Poor oral hygiene, periodontal disease, poorly fitting dentures, history of dental disease, invasive dental procedures, e.g. tooth extractions.</p><p>All patients should be encouraged to maintain good oral hygiene, undergo routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling, non-healing of sores or discharge during treatment with zoledronic acid. While on treatment, invasive dental procedures should be performed with caution and avoided in close proximity to zoledronic acid treatment.</p><p>The management plan for patients who develop ONJ should be set up in close collaboration between the treating physician and a dentist or oral surgeon with expertise in ONJ. Temporary interruption of zoledronic acid treatment should be considered until the condition resolves and contributing risk factors are mitigated where possible.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Atypical fractures of the femur</u></em></p><p>Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, primarily in patients receiving long-term treatment for osteoporosis. These transverse or short oblique fractures can occur anywhere along the femur from just below the lesser trochanter to just above the supracondylar flare. These fractures occur after minimal or no trauma and some patients experience thigh or groin pain, often associated with imaging features of stress fractures, weeks to months before presenting with a completed femoral fracture. Fractures are often bilateral; therefore, the contralateral femur should be examined in bisphosphonate- treated patients who have sustained a femoral shaft fracture. Poor healing of these fractures has also been reported.</p><p>Discontinuation of bisphosphonate therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient, based on an individual benefit risk assessment.</p><p>During bisphosphonate treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>General</u></em></p><p>The incidence of post-dose symptoms occurring within the first three days after administration of Zoledronic Acid can be reduced with the administration of paracetamol or ibuprofen shortly following Zoledronic Acid administration.</p><p>Patients being treated with Zoledronic Acid should not be treated with any other medicines containing zoledronic acid or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Osteonecrosis of the external auditory canal</u></em></p><p>Osteonecrosis of the external auditory canal has been reported with bisphosphonates, mainly in association with long-term therapy. Possible risk factors for osteonecrosis of the external auditory canal include steroid use and chemotherapy and/or local risk factors such as infection or trauma. The possibility of osteonecrosis of the external auditory canal should be considered in patients receiving bisphosphonates who present with ear symptoms including chronic ear infections.</p><p>&nbsp;</p><p><em><u>Warning regarding excipients</u></em></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially &ldquo;sodium-free&rdquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies with other medicinal products have been performed. Zoledronic acid is not systemically metabolised and does not affect human cytochrome P450 enzymes <em>in vitro </em>(see section 5.2). Zoledronic acid is not highly bound to plasma proteins (approximately 43-55% bound) and interactions resulting from displacement of highly protein-bound drugs are therefore unlikely.</p><p>Zoledronic acid is eliminated by renal excretion. Caution is indicated when Zoledronic Acid is administered in conjunction with medicinal products that can significantly impact renal function (e.g. aminoglycosides or diuretics that may cause dehydration) (see section 4.4).</p><p>In patients with renal impairment, the systemic exposure to concomitant medicinal products that are primarily excreted via the kidney may increase.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential</p><p>Zoledronic acid is not recommended in women of childbearing potential.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Pregnancy</u></em></p><p>Zoledronic Acid is contraindicated during pregnancy (see section 4.3). There are no adequate data on the use of zoledronic acid in pregnant women. Studies in animals with zoledronic acid have shown reproductive toxicological effects including malformations (see section 5.3). The potential risk for humans is unknown.</p><p>&nbsp;</p><p><em><u>Breast-feeding</u></em></p><p>Zoledronic Acid is contraindicated during breast-feeding (see section 4.3). It is unknown whether zoledronic acid is excreted into human milk.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Women of childbearing potential</u></em></p><p>Zoledronic Acid is not recommended in women of childbearing potential.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Fertility</u></em></p><p>Zoledronic acid was evaluated in rats for potential adverse effects on fertility of the parental and F1 generation. This resulted in exaggerated pharmacological effects considered related to the compound&#39;s inhibition of skeletal calcium mobilisation, resulting in periparturient hypocalcaemia, a bisphosphonate class effect, dystocia and early termination of the study. Thus, these results precluded determining a definitive effect of zoledronic acid on fertility in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions, such as dizziness, may affect the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Summary of the safety profile</u></em></p><p>The overall percentage of patients who experienced adverse reactions were 44.7%, 16.7% and 10.2% after the</p><p>&nbsp;</p><p>first, second and third infusion, respectively. Incidence of individual adverse reactions following the first infusion was: fever (17.1%), myalgia (7.8%), flu-like symptoms (6.7%), arthralgia (4.8%) and headache (5.1%). The incidence of these reactions decreased markedly with subsequent annual doses of zoledronic acid. The majority of these reactions occur within the first three days following zoledronic acid administration. The majority of these reactions were mild to moderate and resolved within three days of the event onset. The percentage of patients who experienced adverse reactions was lower in a smaller study (19.5%, 10.4%, 10.7% after the first, second and third infusion, respectively), where prophylaxis against adverse reactions was used.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Tabulated list of adverse reactions</u></em></p><p>Adverse reactions in Table 1 are listed according to MedDRA system organ class and frequency category.</p><p>Frequency categories are defined using the following convention: very common (&ge;1/10); common (&ge;1/100 to</p><p>&lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p><strong>Table 1</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Infections and infestations</em></strong></p></td><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Influenza, nasopharyngitis</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Blood and lymphatic system disorders</em></strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong><em>Immune system disorders</em></strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><em>Not known**</em></p></td><td style="vertical-align:top"><p>Hypersensitivity reactions including rare cases of bronchoconstriction, urticaria and angioedema, and very rare cases of anaphylactic reaction/shock</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong><em>Metabolism and nutrition disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Common Uncommon </em>Rare = Hypophosphataemia</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Hypocalcaemia*, decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Psychiatric disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Insomnia</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong><em>Nervous system disorders</em></strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><em>Common Uncommon</em></p></td><td style="vertical-align:top"><p>Headache, dizziness Lethargy, paraesthesia, somnolence, tremor, syncope, dysgeusia</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong><em>Eye disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Common Uncommon Rare Not known**</em></p></td><td style="vertical-align:top"><p>Ocular hyperaemia Conjunctivitis, eye pain Uveitis, episcleritis, iritis Scleritis and parophthalmia</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Ear and labyrinth disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Cardiac disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Common Uncommon</em></p></td><td style="vertical-align:top"><p>Atrial fibrillation Palpitations</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong><em>Vascular disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Uncommon Not known**</em></p></td><td style="vertical-align:top"><p>Hypertension, flushing Hypotension (some of the patients had underlying risk factors)</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Respiratory, thoracic and mediastinal disorders</em></strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Cough, dyspnea</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong><em>Gastrointestinal disorders</em></strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><em>Common Uncommon</em></p></td><td style="vertical-align:top"><p>Nausea, vomiting, diarrhoea, Dyspepsia, abdominal pain upper, abdominal pain, gastroesophageal reflux disease,</p><p>constipation, dry mouth, oesophagitis, toothache, gastritis#</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Skin and subcutaneous tissue disorders</em></strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Rash, hyperhydrosis, pruritus, erythema</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:166px"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong><em>Musculoskeletal and connective tissue disorders</em></strong></p></td><td style="vertical-align:top; width:171px"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><em>Common Uncommon Rare Very rare: Not known**</em></p></td><td style="vertical-align:top; width:490px"><p>Myalgia, arthralgia, bone pain, back pain, pain in extremity Neck pain, musculoskeletal stiffness, joint swelling, muscle spasms, musculoskeletal chest pain, musculoskeletal pain, joint stiffness, arthritis, muscular weakness Atypical subtrochanteric and diaphyseal femoral fractures&dagger; (bisphosphonate class adverse reaction) <u>Osteonecrosis of the</u> <u>external auditory canal (bisphosphonate class adverse</u> <u>reaction) </u>Osteonecrosis of the jaw (see sections</p><p>4.4 and 4.8 Class effects)</p></td></tr><tr><td style="vertical-align:top; width:166px"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong><em>Renal and urinary disorders</em></strong></p></td><td style="vertical-align:top; width:171px"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><em>Uncommon Not known**</em></p></td><td style="vertical-align:top; width:490px"><p>Blood creatinine increased, pollakiuria, proteinuria Renal impairment. Rare cases of renal failure requiring dialysis and rare cases with a fatal outcome have been</p><p>reported in patients with pre-existing renal dysfunction or other risk factors such as advanced age, concomitant nephrotoxic medicinal products, concomitant diuretic therapy, or dehydration in the post infusion period (see</p><p>sections 4.4 and 4.8 Class effects)</p></td></tr><tr><td style="vertical-align:top; width:166px"><p><strong>&nbsp;</strong></p><p><strong><em>General disorders and administration site conditions</em></strong></p></td><td style="vertical-align:top; width:171px"><p><strong>&nbsp;</strong></p><p><em>Very Common Common Uncommon Not known**</em></p></td><td style="vertical-align:top; width:490px"><p>Pyrexia, Influenza-like symptoms, chills, fatigue, asthenia, pain, malaise, infusion site reaction, Peripheral oedema, thirst, acute phase reaction, non-cardiac chest pain, Dehydration secondary to post- dose symptoms such as</p><p>fever, vomiting and diarrhea</p></td></tr><tr><td style="vertical-align:top; width:166px"><p><strong><em>Investigations</em></strong></p></td><td style="vertical-align:top; width:171px"><p><em>Common Uncommon</em></p></td><td style="vertical-align:top; width:490px"><p>C-reactive protein increased, Blood calcium decreased</p></td></tr></tbody></table><p># Observed in patients taking concomitant glucocorticosteroids.</p><p>* Common in Paget&#39;s disease only.</p><p>** Based on post-marketing reports. Frequency cannot be estimated from available data.</p><p>&dagger; Identified in post-marketing experience. <em><u>Description of selected adverse reactions Atrial fibrillation</u></em></p><p>In the HORIZON &ndash; Pivotal Fracture Trial [PFT] (see section 5.1), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving zoledronic acid and placebo, respectively. The rate of atrial fibrillation serious adverse events was increased in patients receiving zoledronic acid (1.3%) (51 out of 3,862) compared with patients receiving placebo (0.6%) (22 out of 3,852).</p><p>The mechanism behind the increased incidence of atrial fibrillation is unknown. In the osteoporosis trials (PFT, HORIZON - Recurrent Fracture Trial [RFT]) the pooled atrial fibrillation incidences were comparable between zoledronic acid (2.6%) and placebo (2.1%). For atrial fibrillation serious adverse events the pooled incidences were 1.3% for zoledronic acid and 0.8% for placebo.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Class effects:</strong></p><p><em><u>Renal impairment</u></em></p><p>Zoledronic acid has been associated with renal impairment manifested as deterioration in renal function (i.e. increased serum creatinine) and in rare cases acute renal failure. Renal impairment has been observed following the administration of zoledronic acid, especially in patients with pre-existing renal dysfunction or additional risk factors (e.g advanced age, oncology patients with chemotherapy, concomitant nephrotoxic medicinal products, concomitant diuretic therapy, severe dehydration), with the majority of them receiving a 4 mg dose every 3&ndash;4 weeks, but it has been observed in patients after a single administration.</p><p>In clinical trials in osteoporosis, the change in creatinine clearance (measured annually prior to dosing) and the incidence of renal failure and impairment was comparable for both the zoledronic acid and placebo treatment groups over three years. There was a transient increase in serum creatinine observed within 10 days in 1.8% of</p><p>&nbsp;</p><p>zoledronic acid treated patients versus 0.8% of placebo-treated patients.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Hypocalcaemia</u></em></p><p>In clinical trials in osteoporosis, approximately 0.2% of patients had notable declines of serum calcium levels (less than 1.87 mmol/l) following zoledronic acid administration. No symptomatic cases of hypocalcaemia were observed.</p><p>In the Paget&#39;s disease trials, symptomatic hypocalcaemia was observed in approximately 1% of patients, in all of whom it resolved.</p><p>Based on laboratory assessment, transient asymptomatic calcium levels below the normal reference range (less than 2.10 mmol/l) occurred in 2.3% of zoledronic acid treated patients in a large clinical trial compared to 21% of zoledronic acid treated patients in the Paget&#39;s disease trials. The frequency of hypocalcaemia was much lower following subsequent infusions.</p><p>All patients received adequate supplementation with vitamin D and calcium in the post-menopausal osteoporosis trial, the prevention of clinical fractures after hip fracture trial, and the Paget&#39;s disease trials (see also section 4.2). In the trial for the prevention of clinical fractures following a recent hip fracture, vitamin D levels were not routinely measured but the majority of patients received a loading dose of vitamin D prior to zoledronic acid administration (see section 4.2).</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Local reactions</u></em></p><p>In a large clinical trial, local reactions at the infusion site, such as redness, swelling and/or pain, were reported (0.7%) following the administration of zoledronic acid.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Osteonecrosis of the jaw</u></em></p><p>Cases of osteonecrosis of the jaw have been reported, predominantly in cancer patients treated with medicinal products that inhibit bone resorption, including zoledronic acid (see section 4.4). In a large clinical trial in 7,736 patients, osteonecrosis of the jaw has been reported in one patient treated with Zoledronic acid and one patient treated with placebo. Cases of ONJ have been reported in the post- marketing setting for Zoledronic acid.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Reporting of suspected adverse reactions</u></em></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via submitting completed forms to:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext&rsquo;s: 2317-2356-2353-2354-2334-2340.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical experience with acute overdose is limited. Patients who have received doses higher than those recommended should be carefully monitored. In the event of overdose leading to clinically significant hypocalcaemia, reversal may be achieved with supplemental oral calcium and/or an intravenous infusion of calcium gluconate.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for treatment of bone diseases, bisphosphonates, ATC code: M05BA08</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Mechanism of action</u></em></p><p>Zoledronic acid belongs to the class of nitrogen-containing bisphosphonates and acts primarily on bone. It is an inhibitor of osteoclast-mediated bone resorption.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Pharmacodynamic effects</u></em></p><p>The selective action of bisphosphonates on bone is based on their high affinity for mineralised bone.</p><p>The main molecular target of zoledronic acid in the osteoclast is the enzyme farnesyl pyrophosphate synthase. The long duration of action of zoledronic acid is attributable to its high binding affinity for the active site of farnesyl pyrophosphate (FPP) synthase and its strong binding affinity to bone mineral.</p><p>Zoledronic acid treatment rapidly reduced the rate of bone turnover from elevated post-menopausal levels with the nadir for resorption markers observed at 7 days, and for formation markers at 12 weeks.</p><p>Thereafter bone markers stabilised within the pre- menopausal range. There was no progressive reduction of bone turnover markers with repeated annual dosing.</p><p>&nbsp;</p><p><em><u>Clinical efficacy in the treatment of post-menopausal osteoporosis (PFT)</u></em></p><p>The efficacy and safety of zoledronic acid 5 mg once a year for 3 consecutive years were demonstrated in post- menopausal women (7,736 women aged 65&ndash;89 years) with either: a femoral neck bone mineral density (BMD) with a T-score &le; &ndash;1.5 and at least two mild or one moderate existing vertebral fracture(s); or a femoral neck BMD T- score &le; &ndash;2.5 with or without evidence of existing vertebral fracture(s).</p><p>85% of patients were bisphosphonate-na&iuml;ve. Women who were evaluated for the incidence of vertebral fractures did not receive concomitant osteoporosis therapy, which was allowed for women contributing to the hip and all clinical fracture evaluations. Concomitant osteoporosis therapy included: calcitonin, raloxifene, tamoxifen, hormone replacement therapy, tibolone; but excluded other bisphosphonates. All women received 1,000 to 1,500 mg elemental calcium and 400 to 1,200 IU of vitamin D supplements daily.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Effect on morphometric vertebral fractures</u></em></p><p>Zoledronic acid significantly decreased the incidence of one or more new vertebral fractures over three years and as early as the one-year timepoint (see Table 2).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 2 Summary of vertebral fracture efficacy at 12, 24 and 36 months</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Outcome</p></td><td style="vertical-align:top"><p>zoledronic acid (%)</p></td><td style="vertical-align:top"><p>Placeb o</p></td><td style="vertical-align:top"><p>Absolute reduction in fracture incidence % (CI)</p></td><td style="vertical-align:top"><p>Relative reduction in fracture incidence % (CI)</p></td></tr><tr><td style="vertical-align:top"><p>At least one new vertebral fracture (0&ndash;1 year)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>1.5</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>3.7</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>2.2 (1.4, 3.1)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>60 (43, 72)**</p></td></tr><tr><td style="vertical-align:top"><p>At least one new vertebral fracture (0&ndash;2 year)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>2.2</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>7.7</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>5.5 (4.4, 6.6)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>71 (62, 78)**</p></td></tr><tr><td style="vertical-align:top"><p>At least one new vertebral fracture (0&ndash;3 year)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>3.3</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>10.9</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>7.6 (6.3, 9.0)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>70 (62, 76)**</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>** p &lt;0.0001</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Zoledronic acid treated patients aged 75 years and older exhibited a 60% reduction in the risk of vertebral fractures compared to placebo patients (p&lt;0.0001).</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Effect on hip fractures</u></em></p><p>Zoledronic acid demonstrated a consistent effect over 3 years, resulting in a 41% reduction in the risk of hip fractures (95% CI, 17% to 58%). The hip fracture event rate was 1.44% for zoledronic acid-treated patients compared to 2.49% for placebo- treated patients. The risk reduction was 51% in bisphosphonate-na&iuml;ve patients and 42% in patients allowed to take concomitant osteoporosis therapy.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Effect on all clinical fractures</u></em></p><p>All clinical fractures were verified based on the radiographic and/or clinical evidence. A summary of results is presented in Table 3.</p><p>&nbsp;</p><p><strong>Table 3 Between treatment comparisons of the incidence of key clinical fracture variables over 3 years</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Outcome</p></td><td style="vertical-align:top"><p>zoledronic acid (N=3,875) event rate (%)</p></td><td style="vertical-align:top"><p>Placebo (N=3,861) event rate (%)</p></td><td style="vertical-align:top"><p>Absolute reduction in fracture event rate % (CI)</p></td><td style="vertical-align:top"><p>Relative risk reduction in fracture incidence % (CI)</p></td></tr><tr><td style="vertical-align:top"><p>Any clinical fracture (1)</p></td><td style="vertical-align:top"><p>8.4</p></td><td style="vertical-align:top"><p>12.8</p></td><td style="vertical-align:top"><p>4.4 (3.0, 5.8)</p></td><td style="vertical-align:top"><p>33 (23, 42)**</p></td></tr><tr><td style="vertical-align:top"><p>Clinical vertebral fracture (2)</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>2.1 (1.5, 2.7)</p></td><td style="vertical-align:top"><p>77 (63, 86)**</p></td></tr><tr><td style="vertical-align:top"><p>Non-vertebral fracture (1)</p></td><td style="vertical-align:top"><p>8.0</p></td><td style="vertical-align:top"><p>10.7</p></td><td style="vertical-align:top"><p>2.7 (1.4, 4.0)</p></td><td style="vertical-align:top"><p>25 (13, 36)*</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>*p-value &lt;0.001, **p-value &lt;0.0001 (1)Excluding finger, toe and facial fractures</p><p>(2)Including clinical thoracic and clinical lumbar vertebral fractures</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em><u>Effect on bone mineral density (BMD)</u></em></p><p>Zoledronic acid significantly increased BMD at the lumbar spine, hip, and distal radius relative to treatment with placebo at all timepoints (6, 12, 24 and 36 months). Treatment with zoledronic acid resulted in a 6.7% increase in BMD at the lumbar spine, 6.0% at the total hip, 5.1% at the femoral neck, and 3.2% at the distal radius over 3 years as compared to placebo.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Bone histology</u></em></p><p>Bone biopsies were obtained from the iliac crest 1 year after the third annual dose in 152 post-menopausal patients with osteoporosis treated with zoledronic acid (N=82) or placebo (N=70). Histomorphometric analysis showed a</p><p>&nbsp;</p><p>63% reduction in bone turnover. In patients treated with zoledronic acid, no osteomalacia, marrow fibrosis or woven bone formation was detected. Tetracycline label was detectable in all but one of 82 biopsies obtained from patients on zoledronic acid. Microcomputed tomography (&mu;CT) analysis demonstrated increased trabecular bone volume and preservation of trabecular bone architecture in patients treated with zoledronic acid compared to placebo.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Bone turnover markers</u></em></p><p>Bone specific alkaline phosphatase (BSAP), serum N-terminal propeptide of type I collagen (P1NP) and serum beta-C-telopeptides (b-CTx) were evaluated in subsets ranging from 517 to 1,246 patients at periodic intervals throughout the study. Treatment with a 5 mg annual dose of zoledronic acid significantly reduced BSAP by 30% relative to baseline at 12 months which was sustained at 28% below baseline levels at 36 months. P1NP was significantly reduced by 61% below baseline levels at 12 months and was sustained at 52% below baseline levels at 36 months. B-CTx was significantly reduced by 61% below baseline levels at 12 months and was sustained at 55% below baseline levels at 36 months. During this entire time period bone turnover markers were within the pre-menopausal range at the end of each year. Repeat dosing did not lead to further reduction of bone turnover markers.</p><p>&nbsp;</p><p><em><u>Effect on height</u></em></p><p>In the three-year osteoporosis study standing height was measured annually using a stadiometer. The zoledronic acid group revealed approximately 2.5 mm less height loss compared to placebo (95% CI: 1.6 mm, 3.5 mm) [p&lt;0.0001].</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Days of disability</u></em></p><p>Zoledronic acid significantly reduced the mean days of limited activity and the days of bed rest due to back pain by 17.9 days and 11.3 days respectively compared to placebo and significantly reduced the mean days of limited activity and the days of bed rest due to fractures by 2.9 days and 0.5 days respectively compared to placebo (all p&lt;0.01).</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Clinical efficacy in the treatment of osteoporosis in patients at increased risk of fracture after a recent hip</u> <u>fracture (RFT)</u></em></p><p>The incidence of clinical fractures, including vertebral, non-vertebral and hip fractures, was evaluated in 2,127 men and women aged 50-95 years (mean age 74.5 years) with a recent (within 90 days) low-trauma hip fracture who were followed for an average of 2 years on study medication. Approximately 42% of patients had a femoral neck BMD T-score below -2.5 and approximately 45% of the patients had a femoral neck BMD T-score above -</p><p>2.5. Zoledronic acid was administered once a year, until at least 211 patients in the study population had confirmed clinical fractures. Vitamin D levels were not routinely measured but a loading dose of vitamin D (50,000 to 125,000 IU orally or via the intramuscular route) was given to the majority of patients 2 weeks prior to infusion. All participants received 1,000 to 1,500 mg of elemental calcium plus 800 to 1,200 IU of vitamin D supplementation per day. Ninety-five percent of the patients received their infusion two or more weeks after the hip fracture repair and the median timing of infusion was approximately six weeks after the hip fracture repair. The primary efficacy variable was the incidence of clinical fractures over the duration of the study.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Effect on all clinical fractures</u></em></p><p>The incidence rates of key clinical fracture variables are presented in Table 4.</p><p><strong>Table 4 Between treatment comparisons of the incidence of key clinical fracture variables</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Outcome</p></td><td style="vertical-align:top"><p>zoledronic acid (N=1,065) event rate (%)</p></td><td style="vertical-align:top"><p>Placebo (N=1,062)</p><p>event rate (%)</p></td><td style="vertical-align:top"><p>Absolute reduction in fracture event rate % (CI)</p></td><td style="vertical-align:top"><p>Relative risk reduction in fracture incidence % (CI)</p></td></tr><tr><td style="vertical-align:top"><p>Any clinical fracture (1)</p></td><td style="vertical-align:top"><p>8.6</p></td><td style="vertical-align:top"><p>13.9</p></td><td style="vertical-align:top"><p>5.3 (2.3, 8.3)</p></td><td style="vertical-align:top"><p>35 (16, 50)**</p></td></tr><tr><td style="vertical-align:top"><p>Clinical vertebral fracture (2)</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>3.8</p></td><td style="vertical-align:top"><p>2.1 (0.5, 3.7)</p></td><td style="vertical-align:top"><p>46 (8, 68)*</p></td></tr><tr><td style="vertical-align:top"><p>Non-vertebral fracture (1)</p></td><td style="vertical-align:top"><p>7.6</p></td><td style="vertical-align:top"><p>10.7</p></td><td style="vertical-align:top"><p>3.1 (0.3, 5.9)</p></td><td style="vertical-align:top"><p>27 (2, 45)*</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>*p-value &lt;0.05, **p-value &lt;0.01</p><p>(1)&nbsp; Excluding finger, toe and facial fractures</p><p>(2)&nbsp; Including clinical thoracic and clinical lumbar vertebral fractures</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>The study was not designed to measure significant differences in hip fracture, but a trend was seen towards reduction in new hip fractures.</p><p>All-cause mortality was 10% (101 patients) in the zoledronic acid treated group compared to 13% (141 patients) in the placebo group. This corresponds to a 28% reduction in the risk of all cause mortality (p=0.01).</p><p>The incidence of delayed hip fracture healing was comparable between zoledronic acid (34 [3.2%]) and placebo (29 [2.7%]).</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Effect on bone mineral density (BMD)</u></em></p><p>In the HORIZON-RFT study zoledronic acid treatment significantly increased BMD at the total hip and femoral neck relative to treatment with placebo at all timepoints.</p><p>Treatment with zoledronic acid resulted in an increase in BMD of 5.4% at the total hip and 4.3% at the femoral neck over 24 months as compared to placebo.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Clinical efficacy in men</u></em></p><p>In the HORIZON-RFT study 508 men were randomised into the study and 185 patients had BMD assessed at 24 months. At 24 months a similar significant increase of 3.6% in total hip BMD was observed for patients treated with zoledronic acid as compared to the effects observed in post-menopausal women in the HORIZON-PFT study. The study was not powered to show a reduction in clinical fractures in men; the incidence of clinical fractures was 7.5% in men treated with zoledronic acid versus 8.7% for placebo.</p><p>In another study in men (study CZOL446M2308) an annual infusion of zoledronic acid was non-inferior to weekly alendronate for the percentage change in lumbar spine BMD at month 24 relative to baseline.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Clinical efficacy in osteoporosis associated with long-term systemic glucocorticoid therapy</u></em></p><p>The efficacy and safety of zoledronic acid in the treatment and prevention of osteoporosis associated with long- term systemic glucocorticoid therapy were assessed in a randomised, multicentre, double-blind, stratified, active- controlled study of 833 men and women aged 18-85 years (mean age for men 56.4 years; for women 53.5 years) treated with &gt; 7.5 mg/day oral prednisone (or equivalent). Patients were stratified with respect to duration of glucocorticoid use prior to randomisation (&le; 3 months versus &gt; 3 months). The duration of the trial was one year. Patients were randomised to either zoledronic acid 5 mg single infusion or to oral risedronate 5 mg daily for one year. All participants received 1,000 mg elemental calcium plus 400 to 1,000 IU vitamin D supplementation per day. Efficacy was demonstrated if non- inferiority to risedronate was shown sequentially with respect to the percentage change in lumbar spine BMD at 12 months relative to baseline in the treatment and prevention subpopulations, respectively. The majority of patients continued to receive glucocorticoids for the one year duration of the trial.</p><p>&nbsp;</p><p><em><u>Effect on bone mineral density (BMD)</u></em></p><p>The increases in BMD were significantly greater in the zoledronic acid treated group at the lumbar spine and femoral neck at 12 months compared to risedronate (all p&lt;0.03). In the subpopulation of patients receiving glucocorticoids for more than 3 months prior to randomisation, zoledronic acid increased lumbar spine BMD by 4.06% versus 2.71% for risedronate (mean difference: 1.36% ; p&lt;0.001). In the subpopulation of patients that had received glucocorticoids for 3 months or less prior to randomisation, zoledronic acid increased lumbar spine BMD by 2.60% versus 0.64% for risedronate (mean difference: 1.96% ; p&lt;0.001). The study was not powered to show a reduction in clinical fractures compared to risedronate. The incidence of fractures was 8 for zoledronic acid treated patients versus 7 for risedronate-treated patients (p=0.8055).</p><p>&nbsp;</p><p><em><u>Clinical efficacy in the treatment of Paget&#39;s disease of the bone</u></em></p><p>Zoledronic acid was studied in male and female patients aged above 30 years with primarily mild to moderate Paget&#39;s disease of the bone (median serum alkaline phosphatase level 2.6&ndash;3.0 times the upper limit of the age- specific normal reference range at the time of study entry) confirmed by radiographic evidence.</p><p>The efficacy of one infusion of 5 mg zoledronic acid versus daily doses of 30 mg risedronate for 2 months was demonstrated in two 6-month comparative trials. After 6 months, zoledronic acid showed 96% (169/176) and 89% (156/176) response and serum alkaline phosphatase (SAP) normalisation rates compared to 74% (127/171) and 58% (99/171) for risedronate (all p&lt;0.001).</p><p>In the pooled results, a similar decrease in pain severity and pain interference scores relative to baseline were observed over 6 months for zoledronic acid and risedronate.</p><p>Patients who were classified as responders at the end of the 6-month core study were eligible to enter an extended follow-up period. Of the 153 zoledronic acid treated patients and 115 risedronate-treated patients who entered an extended observation study, after a mean duration of follow-up of 3.8 years from time of dosing, the proportion of patients ending the Extended Observation Period due to the need for re- treatment (clinical judgment) was higher for risedronate (48 patients, or 41.7%) compared with zoledronic acid (11 patients, or 7.2%). The mean time of ending the Extended Observation Period due to the need for Paget&#39;s re-treatment from the initial dose was longer for zoledronic acid (7.7 years) than for risedronate (5.1 years).</p><p>Six patients who achieved therapeutic response 6 months after treatment with zoledronic acid and later experienced disease relapse during the extended follow-up period were re-treated with zoledronic acid after a mean time of 6.5 years from initial treatment to re-treatment. Five of the 6 patients had SAP within the normal range at month 6 (Last Observation Carried Forward, LOCF).</p><p>Bone histology was evaluated in 7 patients with Paget&#39;s disease 6 months after treatment with 5 mg zoledronic acid. Bone biopsy results showed bone of normal quality with no evidence of impaired bone remodelling and no evidence of mineralisation defects. These results were consistent with biochemical marker evidence of normalisation of bone turnover.</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with the reference medicinal products containing zoledronic acid in all subsets of the paediatric population in Paget&#39;s disease of the bone, osteoporosis in post- menopausal women at an increased risk of fracture, osteoporosis in men at increased risk of fracture and prevention of clinical fractures after a hip fracture in men and women (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single and multiple 5 and 15-minute infusions of 2, 4, 8 and 16 mg zoledronic acid in 64 patients yielded the following pharmacokinetic data, which were found to be dose independent.</p><p>&nbsp;</p><p><em><u>Distribution</u></em></p><p>After initiation of the zoledronic acid infusion, plasma concentrations of the active substance increased rapidly, achieving their peak at the end of the infusion period, followed by a rapid decline to &lt; 10% of peak after 4 hours and &lt; 1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak levels.</p><p>&nbsp;</p><p><em><u>Elimination</u></em></p><p>Intravenously administered zoledronic acid is eliminated by a triphasic process: rapid biphasic disappearance from the systemic circulation, with half-lives of t&frac12;&alpha;0.24 and t&frac12;&beta; 1.87 hours, followed by a long elimination phase with a terminal elimination half- life of t&frac12;&gamma; 146 hours. There was no accumulation of the active substance in plasma after multiple doses given every 28 days. The early disposition phases (&alpha; and &beta;, with t&frac12; values above) presumably represent rapid uptake into bone and excretion via the kidneys.</p><p>Zoledronic acid is not metabolised and is excreted unchanged via the kidney. Over the first 24 hours, 39 &plusmn; 16% of the administered dose is recovered in the urine, while the remainder is principally bound to bone tissue. This uptake into bone is common for all bisphosphonates and is presumably a consequence of the structural analogy to pyrophosphate. As with other bisphosphonates, the retention time of zoledronic acid in bones is very long. From the bone tissue it is released very slowly back into the systemic circulation and eliminated via the kidney. The total body clearance is 5.04 &plusmn; 2.5 l/h, independent of dose, and unaffected by gender, age, race or body weight.</p><p>The inter- and intra-subject variation for plasma clearance of zoledronic acid was shown to be 36% and 34%, respectively. Increasing the infusion time from 5 to 15 minutes caused a 30% decrease in zoledronic acid concentration at the end of the infusion, but had no effect on the area under the plasma concentration versus time curve.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Pharmacokinetic/pharmacodynamic relationships</u></em></p><p>No interaction studies with other medicinal products have been performed with zoledronic acid. Since zoledronic acid is not metabolised in humans and the substance was found to have little or no capacity as a direct-acting and/or irreversible metabolism-dependent inhibitor of P450 enzymes, zoledronic acid is unlikely to reduce the metabolic clearance of substances which are metabolised via the cytochrome P450 enzyme systems. Zoledronic acid is not highly bound to plasma proteins (approximately 43-55% bound) and binding is concentration independent. Therefore, interactions resulting from displacement of highly protein-bound drugs are unlikely.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Special populations (see section 4.2) Renal impairment</u></em></p><p>The renal clearance of zoledronic acid was correlated with creatinine clearance, renal clearance representing 75 &plusmn; 33% of the creatinine clearance, which showed a mean of 84 &plusmn; 29 ml/min (range 22 to 143 ml/min) in the 64 patients studied. Small observed increases in AUC(0-24hr), by about 30% to 40% in mild to moderate renal impairment, compared to a patient with normal renal function, and lack of accumulation of drug with multiple doses irrespective of renal function, suggest that dose adjustments of zoledronic acid in mild (Clcr = 50&ndash;80 ml/min) and moderate renal impairment down to a creatinine clearance of 35 ml/min are not necessary. The use of zoledronic acid in patients with severe renal impairment (creatinine clearance &lt; 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Acute toxicity</u></em></p><p>The highest non-lethal single intravenous dose was 10 mg/kg body weight in mice and 0.6 mg/kg in rats. In the single-dose dog infusion studies, 1.0 mg/kg (6 fold the recommended human therapeutic exposure based on AUC) administered over 15 minutes was well tolerated with no renal effects.</p><p>&nbsp;</p><p><em><u>Subchronic and chronic toxicity</u></em></p><p>In the intravenous infusion studies, renal tolerability of zoledronic acid was established in rats when given 0.6 mg/kg as 15-minute infusions at 3-day intervals, six times in total (for a cumulative dose that corresponded to AUC levels about 6 times the human therapeutic exposure) while five 15-minute infusions of 0.25 mg/kg administered at 2&ndash;3-week intervals (a cumulative dose that corresponded to 7 times the human therapeutic exposure) were well tolerated in dogs. In the intravenous bolus studies, the doses that were well-tolerated decreased with increasing study duration: 0.2 and 0.02 mg/kg daily was well tolerated for 4 weeks in rats and dogs, respectively but only 0.01 mg/kg and 0.005 mg/kg in rats and dogs, respectively, when given for 52 weeks.</p><p>Longer-term repeat administration at cumulative exposures sufficiently exceeding the maximum intended human exposure produced toxicological effects in other organs, including the gastrointestinal tract and liver, and at the site of intravenous administration. The clinical relevance of these findings is unknown. The most frequent finding in the repeat-dose studies consisted of increased primary spongiosa in the metaphyses of long bones in growing animals at nearly all doses, a finding that reflected the compound&#39;s pharmacological antiresorptive activity.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Reproduction toxicity</u></em></p><p>Teratology studies were performed in two species, both via subcutaneous administration. Teratogenicity was observed in rats at doses &ge; 0.2 mg/kg and was manifested by external, visceral and skeletal malformations. Dystocia was observed at the lowest dose (0.01 mg/kg body weight) tested in rats. No teratological or embryo/foetal effects were observed in rabbits, although maternal toxicity was marked at 0.1 mg/kg due to decreased serum calcium levels.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Mutagenicity and carcinogenic potential</u></em></p><p>Zoledronic acid was not mutagenic in the mutagenicity tests performed and carcinogenicity testing did not provide any evidence of carcinogenic potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Mannitol</p><p>- Sodium Citrate Dihydrate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be allowed to come into contact with any calcium- containing solutions. Zoledronic Acid must not be mixed or given intravenously with any other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30˚C</p><p>After opening the bag, the product should be used immediately in order to avoid microbial contamination. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2&deg;C - 8&deg;C. Allow the refrigerated solution to reach room temperature before administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zoledronic Acid 5 mg/100 ml comes in 100 ml clear colorless solution free from visible extraneous matter, filled in USP Type-I Tubular Glass Vial</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For single use only.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements. Only clear solution free from particles and discoloration should be used.</p><p>If refrigerated, allow the refrigerated solution to reach room temperature before administration. Aseptic techniques must be followed during the preparation of the infusion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sudair Pharma Company (SPC)
King Fahad road, Building 911- The First Round Riyadh, Saudi Arabia Tel: +966-11-920001432
Fax: +966-11-4668195
Email: info@sudairpharma.com
Mailing: P.O. Box 19047 Riyadh, Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>